AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$289.83
+$1.01 (+0.35%) 4:00 PM ET
Prev closePrevC$288.82
OpenOpen$288.33
Day highHigh$290.22
Day lowLow$284.73
VolumeVol1,914,205
Avg volAvgVol1,769,885
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$76.36B
P/E ratio
12.82
FY Revenue
$267.09B
EPS
22.61
Gross Margin
9.22%
Sector
Healthcare
AI report sections
BULLISH
CI
The Cigna Group
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+45% (Above avg)
Vol/Avg: 1.45×
RSI
55.75(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.08 (Strong)
MACD: 0.08 Signal: -0.00
Short-Term
-0.49 (Weak)
MACD: 2.13 Signal: 2.62
Long-Term
-0.16 (Weak)
MACD: 3.73 Signal: 3.89
Intraday trend score
74.00
LOW54.00HIGH75.00
Latest news
CI•12 articles•Positive: 3Neutral: 6Negative: 3
PositiveInvesting.com• Timothy Fries
Cummins Revenue Holds Up as Charges Weigh on Near-Term Earnings Clarity
In recent earnings releases, KKR reported strong revenue of $5.74B (beating $2.11B expectations) but missed on EPS at $1.12 vs $1.14 expected. Cummins exceeded revenue expectations at $8.5B but fell short on EPS at $4.27 vs $5.01 expected due to Electrolyzer business charges. The Cigna Group outperformed on both metrics with $72.47B revenue and $8.08 EPS, demonstrating strong operational discipline.
Strong financial performance with both revenue ($72.47B) and EPS ($8.08) exceeding expectations. Total 2025 revenues increased 11% year-over-year, adjusted operating income reached $8.0B, and company increased quarterly dividend, demonstrating operational discipline and positive outlook.
PositiveBenzinga• Vandana Singh
FTC Settlement With Cigna's Pharmacy Benefit Manager Promises Cheaper Insulin, Boosts Dividend On Strong Quarterly Earnings
The FTC finalized a settlement with Cigna's Express Scripts pharmacy benefit manager to reduce anticompetitive practices and lower insulin costs by up to $7 billion over the next decade. Cigna reported strong Q4 2025 earnings, beating revenue and EPS estimates, and increased its quarterly dividend to $1.56 per share. The stock rose 3.53% following the announcement.
Strong Q4 earnings beat (revenue $72.49B vs $69.83B estimate; EPS $8.08 vs $7.88 estimate), 10% YoY revenue growth, 16% increase in operating income, dividend increase to $1.56/share, and stock up 3.53%. FTC settlement provides regulatory clarity and positions the company favorably for future operations.
NegativeGlobeNewswire Inc.• National Community Pharmacists Association
Boom! FTC Squeezes Concessions from Cigna’s Express Scripts
The FTC has secured a landmark settlement with Cigna's Express Scripts requiring elimination of spread pricing, decoupling rebates from drug list prices, relocating its GPO from Switzerland to the U.S., and adopting a cost-plus reimbursement model for independent pharmacies starting in 2027. The NCPA views this as a major victory against anticompetitive PBM practices that have artificially inflated drug prices and harmed independent pharmacies.
Cigna and its Express Scripts subsidiary face significant regulatory penalties including elimination of spread pricing, decoupling of rebates from list prices, relocation of its GPO, and mandatory cost-plus reimbursement model adoption. These concessions represent substantial business practice restrictions and 10 years of FTC monitoring, indicating regulatory pressure and potential financial impact.
NegativeBenzinga• Vandana Singh
FTC Delays Drug Middlemen Case While Talks Move Forward
The FTC has paused its administrative case against major pharmacy benefit managers (PBMs) including Cigna, CVS Health, and UnitedHealth Group, suggesting settlement negotiations may be underway. The 14-day suspension delays the evidentiary hearing to July 1. The case, filed in September 2024, accuses PBMs of unfair practices that inflated insulin prices. Recent investigations and political pressure from the Trump administration have intensified scrutiny on PBM practices, particularly regarding markups on specialty drugs and alleged use of shell companies to obscure profits.
Company is a defendant in the FTC case alleging unfair pricing practices and is under investigation for using shell companies to obscure profits. The case pause suggests potential settlement negotiations, which could result in penalties or operational changes.
NeutralBenzinga• Vandana Singh
UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates
UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.
Mentioned as appearing before House panels alongside other insurers but no specific company actions or statements reported in the article.
NegativeBenzinga• Erica Kollmann
Are CVS, UnitedHealth, Cigna Hiding Billions In PBM Rebates? New Report Claims They Are
A new report from Hunterbrook Media alleges that CVS Health, UnitedHealth Group, and Cigna are using shell subsidiary companies called GPOs (Group Purchasing Organizations) to hide billions of dollars in drug rebates that should be passed to patients. The report claims these companies collect massive fees through their GPOs while telling customers they've passed on 100% of rebates, effectively siphoning off drug discounts meant for patients. Hunterbrook visited the GPO headquarters in Ireland, Switzerland, and Minnesota, finding mostly empty offices despite handling tens of billions in revenue.
Implicated in the scheme to hide billions in rebates through GPO subsidiaries, with reports of uncooperative behavior when questioned.
PositiveBenzinga• Vandana Singh
Cigna Offers Cleaner Growth Than Other Health Insurers, Says Analyst
BofA Securities highlighted Cigna's strong potential in commercial health insurance, noting its pharmacy benefit management platform and ability to deliver 10-15% annual EPS growth, while also discussing challenges and opportunities in the healthcare insurance market.
Offers clean exposure to commercial health insurance, positioned for 10-15% EPS growth, trades at attractive valuation, and has less government exposure compared to peers
NeutralThe Motley Fool• Patrick Sanders
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026
UnitedHealth Group's stock has dropped 35% in 2025 due to misjudged medical service costs, but the company plans to improve profit margins in 2026-2027 by adjusting Medicare Advantage bids and negotiating better rates.
Mentioned as a market competitor with no detailed performance discussion
NeutralBenzinga• Vandana Singh
White House Set To Unveil Framework To Extend Obamacare Subsidies
The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.
Abeona Therapeutics saw a significant stock surge of over 25% after reporting strong Q3 earnings and positive updates on Zevaskyn, its gene therapy treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with major insurers now covering the treatment.
Mentioned as one of the commercial payers covering Zevaskyn treatment
NeutralBenzinga• Vishaal Sanjay
UnitedHealth's $4.3 Billion Profit Fueled By 'Generosity Of Uncle Sam,' Says Healthcare Activist: Government Drives 78% Of Health Plan Revenue
UnitedHealth reported $113 billion in revenue and $4.3 billion profit in Q3, with healthcare activist Wendell Potter criticizing the company's heavy reliance on government funding, which comprises 78% of its health plan revenues.
Mentioned as one of the insurance carriers Smart Medigap Plans partners with, without specific positive or negative context
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal